Rimiterol

Rimiterol (INN/USAN) is a third-generation[1] short-acting[2][3] β2 agonist.

Rimiterol
Clinical data
Pregnancy
category
  • AU: A
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
Identifiers
IUPAC name
  • 4-{(S)-hydroxy[(2R)-piperidin-2-yl]methyl}benzene-1,2-diol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.046.627
Chemical and physical data
FormulaC12H17NO3
Molar mass223.272 g·mol−1
3D model (JSmol)
SMILES
  • O[C@@H](c1ccc(O)c(O)c1)[C@@H]2NCCCC2
InChI
  • InChI=1S/C12H17NO3/c14-10-5-4-8(7-11(10)15)12(16)9-3-1-2-6-13-9/h4-5,7,9,12-16H,1-3,6H2/t9-,12+/m1/s1 Y
  • Key:IYMMESGOJVNCKV-SKDRFNHKSA-N Y
 NY (what is this?)  (verify)

See also

References
  1. Palma-Carlos AG, Palma-Carlos GS (April 1986). "Beta-2-agonists of third generation". Allergie et Immunologie. 18 (4): 31–2, 35. PMID 2899434.
  2. Lai CK, Twentyman OP, Holgate ST (October 1989). "The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness". The American Review of Respiratory Disease. 140 (4): 917–23. doi:10.1164/ajrccm/140.4.917. PMID 2572192.
  3. Ydreborg SO, Svedmyr N, Thiringer G (April 1977). "Comparison of rimiterol and terbutaline, given by aerosol, in a long-term study". Scandinavian Journal of Respiratory Diseases. 58 (2): 117–24. PMID 16339.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.